Eli Lilly Publishes Results of Tirzepatide in P-III (SURMOUNT-1) Trial for the Treatment of Obesity or Overweight in the NEJM
Shots:
- The P-III (SURMOUNT-1) trial evaluating tirzepatide (5/10/15mg) vs PBO in a ratio (1:1:1:1) in 2539 patients with obesity or overweight across the US, India & 7 other countries
- The trial met its co-primary & 2EPs for the efficacy & treatment-regimen estimand i.e., avg. weight reductions (16.0% & 15.0%/21.4% & 19.5%/21.4% & 20.9% vs 22.5% & 3.1%); 5% & ≥5% in (89% & 85%/96% & 89%/96% & 91% vs 28% & 35%)
- 10% body weight reductions (73% & 69%/86% & 78%/90% & 84% vs 14% & 19%); 15% & ≥15% in (50% & 48%/74% & 67%/78% & 71% vs 6.0% & 9%); 20% & ≥20% in (32% & 30%/55% & 50%/63% & 57% vs 1.3% & 3.1%) while 25% for efficacy (16.5%/35%/39.7% vs 0.3%), 33.9% fat mass reduction over 10.9% lean mass
Ref: PRNewswire| Image: Eli Lilly
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
